North America to Dominate the Renal Replacement Therapy Market

Sat, 18 July 2020 12:30

Renal replacement therapy was introduced in the late 1970s.Burton introduced the term hemofiltration in 1976 and conducted the first multicenter trial to test its accuracy and effectiveness in the same year. Continuous arteriovenous hemofiltration (CAVH) was adopted in 1977 to treat patients with acute renal failure.In addition, CAVH also can preserve hemodynamic stability in critically illpatients.

Kidney disease is now recognized as an endemic problem of public health, affecting more than 850 million people across the globe. The Centers for Disease Control and Prevention (CDC) reported that chronic kidney disease (CKD) affects 15% of the U.S. adults, around 37 million people. Every day, in the U.S., about 13 patients die while waiting for a kidney transplant and renal replacement therapy. The demand for renal replacement therapies has enhanced as its products are helping surgeons to remove solutes in blood and tissue. Apart from this, rising cases of acute kidney injury (AKI), favorable reimbursement policies, and technological advancements in renal replacement therapy systems drive the market growth.

Got questions about your regional growth of

Renal Replacement Therapy Market?

Just drop us a line or call on +1 646 480 7505

Impact COVID-19

The renal replacement therapy market is facing a shortage in the supply of products and consumables used in therapy due to the coronavirus outbreak. The market is estimated to witness revenue loss due to declining inpatient hospital services for renal replacements as most of the beds are occupied by COVID-19 patients. However, Fresenius Medical Care announced plans to assemble a national pool of 150 dialysis machines, which can be deployed to U.S. hospitals.

Key Highlights

  • The renal replacement therapy marketwas valued at USD 923.4 million in 2019 and is expected to grow with a CAGR of 7.4% on account of growing prevalence of renal diseases and surging geriatric population
  • The consumable segment dominates the market on account of their high replacement rate
  • The continuous venovenous hemofiltration (CVVH) segment holds sthe largest market share on account of increasing incidences of fluid overload cases.
  • North America dominates the renal replacement therapy market as the region is backed by the presence of increasing demand for RRT procedures and technologically advanced products

Key Players

  • Fresenius Medical Care
  • Baxter International
  • Medtronic
  • BraunMelsungen
  • Asahi Kasei Corporation
  • Infomed, Medica
  • Medical Components
  • Medites
  • Nikkiso
  • Nxtstage
  • Toray

Recent Development

  • In September 2019, Helath Canada has approved The PrisMax system used in ICU developed by Baxter international for the treatment of  acute kidney injury (AKI).This approval would enable company to achieve market share and generate sales as the company has streamlined therapy and maximized accuracy and performance.
  • In September 2019, Baxter received approval for The PrisMax system from Health Canada to treat kidney injury (AKI) in the ICU. The approval will help company to increase market presence and revenue generation as the company has simplified therapy and maximized accuracy and efficiency.

Renal Replacement Therapy Market: Segmentation

By Product

  • System
  • Consumables

By Modality

  • Slow continuous ultrafiltration
  • Continuous veno-venous hemofiltration
  • Continuous veno-venous hemodialysis
  • Continuous veno-venous hemodiafiltration

By Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • The Middle East and Africa

" Crucial Insights The Report Provides:"

* Known and Unknown Adjacencies Influencing the Growth of Market

* Explorable Revenue Sources

* Customer Behaviour Analysis

* Target Partners

* Customized Geographical Data Based on Customers as well as Competitors

* Analysis of Market Size and CAGR between the Forecast Periods

View Full Report Buy This Report Now